Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients

MLA

Tjip S. van der Werf, et al. Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid Resistant/Intolerant Tuberculosis Patients. Feb. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....15a9f9ff8a8cc9d29e04b52704049c4b&authtype=sso&custid=ns315887.

APA

Tjip S. van der Werf, Dick van Soolingen, Marieke G G Sturkenboom, Onno W. Akkerman, Richard M. Anthony, Wiel C M de Lange, Mathieu S. Bolhuis, Vanessa B Vogensen, Huib A. M. Kerstjens, & Jan-Willem C. Alffenaar. (2022). Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients.

Chicago

Tjip S. van der Werf, Dick van Soolingen, Marieke G G Sturkenboom, Onno W. Akkerman, Richard M. Anthony, Wiel C M de Lange, Mathieu S. Bolhuis, Vanessa B Vogensen, Huib A. M. Kerstjens, and Jan-Willem C. Alffenaar. 2022. “Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid Resistant/Intolerant Tuberculosis Patients,” February. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....15a9f9ff8a8cc9d29e04b52704049c4b&authtype=sso&custid=ns315887.